Top Markets
#1 Islamic Coin Islamic Coin +151.56%
#2 Black Phoenix Black Phoenix +35.83%
#3 Palladium Network Palladium Network +20.31%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.14%
#5 Akedo Akedo +16.13%
#6 Fake World Assets Fake World Assets +12.92%
#7 OpenEden OpenEden +12.68%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.64%
#9 clBTC clBTC +12.01%
#10 Arowana Arowana +11.93%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Classifica tra le azioni #39945
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Prezzo delle azioni
$0.00366968
Ultima sincronizzazione: 2024-07-23
Capitalizzazione di mercato
$291.42K
Variazione (1 giorno)
-0.81%
Variazione (1 anno)
0.00%
Paese
US
Scambia Bioasis Technologies Inc. (BTI)

Categoria

Healthcare
Storico del rendimento da dividendi per Bioasis Technologies Inc. (BTI)
Il rendimento da dividendi (TTM) di Bioasis Technologies Inc. (simbolo azionario: BTI) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Bioasis Technologies Inc. (BTI) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
0.65%
BE